Baidu
map

JCEM:血浆无细胞DNA可区分恶性和良性甲状腺结节

2021-01-27 MedSci原创 MedSci原创

血浆cfDNA可以帮助区分恶性和良性甲状腺结节。

分子检测越来越广泛地用于甲状腺结节(特别是不确定类别)良恶性鉴定。血浆中无细胞DNA(cfDNA)水平已用于诊断其他器官/组织的癌症。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究对甲状腺结节患者的cfDNA水平进行评估,并以明确用于识别恶性肿瘤的临界值。

研究人员对甲状腺结节患者进行超声检查(USG)和USG指导的细针穿刺术(FNA)检查,并在需要时进行手术。研究人员从受试者血浆中提取无细胞的DNA并进行定量。在初步分析(确定临界值)中,研究人员比较了Bethesda 2级患者和Bethesda 5-6级患者的cfDNA水平,以确定可区分恶性结节与良性结节的临界值。在随后的分析中,研究人员对不确定结节的患者应用上述截止值(截止值验证)以评估预测恶性肿瘤的能力。

研究人员进行了FNA(n=119)及组织病理学检查,Bethesda 2患者(n=69)和Bethesda 5-6患者( n=13)。两组患者的无细胞DNA分别为22.85±1.27和96.20±8.31(ng/ml)。cfDNA临界值为67.9 ng/ml,AUC为0.992(95%CI为0.97-1.0),其灵敏度为100%,特异性为93%,可用于识别恶性病变。不确定的(Bethesda 3和4)甲状腺结节患者进行了手术(恶性n=24),(良性n=13),并且使用先前确定的cfDNA临界值,研究人员能够以100%的敏感性和92.3%的特异性识别出恶性病变。基于cfDNA的分类与基于组织病理学检查的良性和恶性结节分类的结果一致(Cohen’s kappa指数为0.94,p<0.001)。

由此可见,血浆cfDNA可以帮助区分恶性和良性甲状腺结节

原始出处:

Susmita Dutta.et al.Plasma cell free DNA to differentiate malignant from benign thyroid nodules.JCEM.2021.https://doi.org/10.1210/clinem/dgab030

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778013, encodeId=f6881e7801308, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Nov 17 18:10:12 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063395, encodeId=1c172063395ae, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Aug 22 22:10:12 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920242, encodeId=22b992024236, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da265312566, createdName=1488e725m00暂无昵称, createdTime=Wed Jan 27 10:16:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920241, encodeId=31239202410d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Wed Jan 27 10:15:29 CST 2021, time=2021-01-27, status=1, ipAttribution=)]
    2021-11-17 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778013, encodeId=f6881e7801308, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Nov 17 18:10:12 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063395, encodeId=1c172063395ae, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Aug 22 22:10:12 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920242, encodeId=22b992024236, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da265312566, createdName=1488e725m00暂无昵称, createdTime=Wed Jan 27 10:16:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920241, encodeId=31239202410d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Wed Jan 27 10:15:29 CST 2021, time=2021-01-27, status=1, ipAttribution=)]
    2021-08-22 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778013, encodeId=f6881e7801308, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Nov 17 18:10:12 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063395, encodeId=1c172063395ae, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Aug 22 22:10:12 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920242, encodeId=22b992024236, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da265312566, createdName=1488e725m00暂无昵称, createdTime=Wed Jan 27 10:16:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920241, encodeId=31239202410d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Wed Jan 27 10:15:29 CST 2021, time=2021-01-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778013, encodeId=f6881e7801308, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Wed Nov 17 18:10:12 CST 2021, time=2021-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063395, encodeId=1c172063395ae, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sun Aug 22 22:10:12 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920242, encodeId=22b992024236, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da265312566, createdName=1488e725m00暂无昵称, createdTime=Wed Jan 27 10:16:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920241, encodeId=31239202410d, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=233e5432985, createdName=JMR666, createdTime=Wed Jan 27 10:15:29 CST 2021, time=2021-01-27, status=1, ipAttribution=)]
    2021-01-27 JMR666

    0

相关资讯

Mol Med Rep:螺旋藻-姜黄素-波斯菊治疗良性甲状腺结节的效果

良性甲状腺结节是最常见的内分泌疾病之一,影像学和病理学诊断的最新进展极大地促进了甲状腺结节风险分层的改善。然而,除了手术方法外,目前的治疗方案是有限的。本研究为一项为期3个月的双盲、安慰剂对照研究,评

甲状腺结节TI-RADS分级解读

TI-RADS(Thyroid imaging reporting and data system)即甲状腺影像报告和数据系统。依据五个甲状腺结节恶性特征进行分级:1、实性结节;2、低回声或极低回声;

Mol Med Rep:螺旋藻-姜黄素-波斯菊能有效地减少良性甲状腺结节的大小

良性甲状腺结节是最常见的内分泌疾病之一。影像学和病理学诊断的最新进展极大地促进了甲状腺结节风险分层的改善。然而,除了手术方法外,目前的治疗方案是有限的。以下研究首次介绍了一种非侵入性疗法治疗良性甲状腺

甲状腺结节是良性还是恶性?问5个问题就能搞清!

2万个甲状腺结节总结出的经验,5个问题搞定结节良恶性!

肺结节、甲状腺结节、乳腺结节,到底切不切?一次性告诉你

很多人一听到“结节”就会惊慌失措,显然是把它与癌症放在一起,所以听起来让人觉得害怕。

Thyroid:二甲双胍在治疗甲状腺结节和胰岛素抵抗患者中的作用

由此可见,二甲双胍可诱导甲状腺结节和胰岛素抵抗患者甲状腺结节缩小和TSH、HOMA-IR水平降低。相反,未发现甲状腺体积变化。二甲双胍治疗甲状腺结节是否具有临床意义仍有待证实。

Baidu
map
Baidu
map
Baidu
map